financetom
Business
financetom
/
Business
/
Form 8.3 - ALPHA GROUP INTERNATIONAL PLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - ALPHA GROUP INTERNATIONAL PLC
Oct 13, 2025 7:09 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Verition Fund Management LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

ALPHA GROUP INTERNATIONAL PLC

 

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10 October 2025

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No – holdings and dealings in the Offeror are not disclosable.

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

0.2p Ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

 

(2) Cash-settled derivatives:

 

677,815

1.60

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

677,815

1.60

 

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions)

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

(USD)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security

Product description

Nature of dealing

Number of reference securities

Price per unit

e.g. CFD

e.g. opening/closing a long/short position, increasing/reducing a long/short position

(GBp)

0.2p Ordinary

CFD

Increasing a long position

187

4201.97

 

 

 

 

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

0.2p Ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

 

(2) Cash-settled derivatives:

 

677,815

1.60

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

677,815

1.60

 

 

 

0

Class of relevant security:

 

0.2p Ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

 

(2) Cash-settled derivatives:

 

677,815

1.60

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

677,815

1.60

 

 

 

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Verition Fund Management LLC

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Italy to change web tax in bid to overcome US objections
Italy to change web tax in bid to overcome US objections
Nov 9, 2024
ROME, Nov 7 (Reuters) - Italy has extended its domestic tax on digital services to small and medium-sized enterprises (SMEs) to try to overcome U.S. objections that the levy is discriminatory, Economy Minister Giancarlo Giorgetti said on Thursday. Washington has threatened tariffs over unilateral digital taxes in Europe, as they mainly target U.S. tech companies such as Meta Platforms (...
Haemonetics Fiscal Q2 Adjusted Earnings, Revenue Rise
Haemonetics Fiscal Q2 Adjusted Earnings, Revenue Rise
Nov 9, 2024
08:53 AM EST, 11/07/2024 (MT Newswires) -- Haemonetics ( HAE ) reported fiscal Q2 adjusted earnings Thursday of $1.12 per diluted share, up from $0.99 a year earlier. Analysts polled by Capital IQ expected $1.07. Net revenue for the quarter ended Sept. 28 was $345.5 million, up from $318.2 million. Analysts polled by Capital IQ expected $342.6 million. The company...
Immunovant Fiscal Q2 Net Loss Widens
Immunovant Fiscal Q2 Net Loss Widens
Nov 9, 2024
08:56 AM EST, 11/07/2024 (MT Newswires) -- Immunovant ( IMVT ) reported a fiscal Q2 net loss Thursday of $0.74 per diluted share, widening from a loss of $0.45 a year earlier. Analysts polled by Capital IQ expected a loss of $0.60. The clinical-stage immunology company didn't report any revenue for the quarter ended Sept. 30, as expected by analysts...
Evergy beats Q3 profit estimates on higher power demand
Evergy beats Q3 profit estimates on higher power demand
Nov 9, 2024
Nov 7 (Reuters) - Electric utility Evergy ( EVRG ) beat Wall Street estimates for third-quarter profit on Thursday, on the back of higher power demand which the company expects will continue to significantly increase in the next few years. The U.S. Energy Information Administration estimated power consumption will reach record highs in 2024 and 2025, driven by growing demand...
Copyright 2023-2026 - www.financetom.com All Rights Reserved